Proteogenix is currently developing non-invasive protein biomarker screening tests for intra-amniotic infection, premature birth, and Down syndrome, which combined cause 175,000 premature births each year in the United States alone.
Proteogenix is currently developing non-invasive protein biomarker screening tests for intra-amniotic infection, premature birth, and Down syndrome. The development of these tests could lead to the prevention of 175,000 premature births each year in the United States alone.